{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"9.5","upperLimit":"NA","value":"12.9"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"7.7","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"186"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Abemaciclib 150 mg administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.","id":"OG000","title":"Arm A: Abemaciclib Plus Fulvestrant"},{"description":"Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.","id":"OG001","title":"Arm B: Placebo Plus Fulvestrant"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)","title":"Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}